ArticleThe AAPS journal2026
Industry Practices in Oligonucleotide Tissue Biodistribution Assessment: An IQ consortium Cross-Industry Survey of Current Approaches and Emerging Trends.
Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate assessment of tissue distribution for oligonucleotide therapeutic (ONT) drug candidates is essential for understanding pharmacokinetic behavior and predicting therapeutic efficacy. ONTs present a unique challenge with their rapid systemic clearance coupled with prolonged tissue retention, making comprehensive tissue concentration evaluation critical for successful drug development. The IQ Consortium Tissue Concentration Working Group surveyed member companies about their current tissue concentration assessment methods to understand industry practices and identify areas for improvement. Most companies reported that ONTs still represent a relatively small portion of their pre-candidate selection portfolios, reflecting the evolving nature of this therapeutic modality. siRNAs dominated development efforts across surveyed organizations, followed by antisense oligonucleotides, indicating clear therapeutic class preferences within the industry. Assessment strategies varied considerably across organizations, highlighting different approaches to resource allocation and risk management. While some companies routinely evaluate tissue concentrations for all ONT programs regardless of indication or target, others take a more selective, program-dependent approach based on compound characteristics and therapeutic objectives. Despite this strategic variability, there was universal reliance on LC-MS for quantification, often supplemented with qPCR/RT-qPCR and hybridization assays for comprehensive analytical coverage. All surveyed companies integrate tissue concentration data into translational pharmacokinetic modeling efforts, yet few have adopted physiologically-based pharmacokinetic (PBPK) models as standard practice. Companies recognize the value of improving ONT tissue distribution assessment through standardized methodology tailored to specific oligonucleotide classes.
Indexed as
Identifiers
41612090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.